The Icahn School of Medicine at Mount Sinai (ISMMS) was awarded a $676,000 Project Grant by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "EPIGENETIC STUDIES OF CANDIDATE CELLS OF ORIGIN FOR DIFFUSE MIDLINE GLIOMA," is for a research project spanning from September 1, 2024, to August 31, 2026. The funding will support ISMMS's investigation into epigenetic factors that contribute to the development of diffuse midline glioma, an aggressive form of brain cancer. As a renowned academic medical center, ISMMS has a strong focus on translational research and a history of collaborating with federal agencies on various medical research initiatives.
Generated 1/28/25, 8:46 AM